Drug or intervention
Amlodipine Clinical Trials
Studies that test Amlodipine, alone, with other treatments or as the comparison.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 50Hypertension (HTN), Hypertension
A Study to Evaluate the Effectiveness and Safety of S-amlodipine-based Monotherapy and Combination Therapy
This study aims to evaluate the effectiveness, safety, and clinical utility as a treatment strategy of the s-amlodipine-based monotherapy, dual combination, and triple combination in patients with hypertension across various…
- Conditions
- Hypertension (HTN), Hypertension, Essential (Primary) Hypertension
- Trial name
- STRIKE (NCT07907822)
- Volunteers
- 4,528 people
- Sponsor
- Ahn-Gook Pharmaceuticals Co.,Ltd
Endothelial Dysfunction, End-Stage Renal Disease
Ramipril vs. Amlodipine in Pediatric Hemodialysis Patients
The goal of this clinical trial is to learn if Ramipril works better than Amlodipine to reduce endothelial dysfunction in pediatric patients (aged 5-18 years) with end-stage kidney disease undergoing maintenance hemodialysis and…
- Conditions
- Endothelial Dysfunction, End-Stage Renal Disease, Pediatric Kidney Disease
- Trial name
- ADMA /PedsQL (NCT07879560)
- Testing
- Ramipril tablet, Amlodipine tablet
- Volunteers
- 50 people
- Sponsor
- Ain Shams University
Primary Aldosteronism
Comparing Inclisiran Versus Statin for Primary Aldosteronism
Primary aldosteronism represents one of the leading causes of resistant hypertension. Circulating cholesterol is established as the exclusive substrate for adrenal aldosterone synthesis, and statins, which suppress cholesterol…
- Trial name
- NCT07884955
- Testing
- inclisiran, Lipophilic statins (such as Simvastatin, Atorvastatin, Fluvastatin, Lovastatin,Pitavastatin), Spironolactone (drug)
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Third Military Medical University
Hypertension
Sitogilun Malate Plus Amlodipine in Patients With Hypertension and Risk of Early Kidney Damage
This is a multicenter, randomized, double-blind, parallel-controlled Phase IV clinical trial designed to evaluate the efficacy and safety of sitogilun malate tablets in combination with amlodipine besylate tablets in patients…
- Trial name
- SABER (NCT07876544)
- Testing
- Sitogilun Malate, Allisartan Isoproxil, Amlodipine besylate
- Where
- China
- Volunteers
- 456 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Hypertension
SPIRO-First: A Pragmatic Primary Care-Embedded Pilot Trial of Renin-Guided First-Line Antihypertensive Therapy
The goal of this clinical trial is to determine whether a renin-guided antihypertensive treatment strategy is feasible to implement in community primary care clinics and to explore whether spironolactone improves blood pressure…
- Trial name
- SPIRO-First (NCT07687160)
- Testing
- Spironolactone (drug), Candesartan 8mg, Hydrochlorothiazide (HCTZ) 25 milligrams.
- Where
- 4 sites in Canada
- Volunteers
- 30 people
- Sponsor
- Ottawa Hospital Research Institute
Hypertension, Dyslipidemia
Polypills Approach for Multiple Cardiovascular Risk Factors
The Polypill Approach for Multiple Cardiovascular Risk Factors (PACIF) trial is a multicenter randomized controlled trial that will test the effectiveness and safety of a fixed-dose combination strategy for the integrated…
- Conditions
- Hypertension, Dyslipidemia, Diabetes
- Trial name
- PACIF (NCT07679828)
- Testing
- Fixed-Dose Combination Strategy
- Where
- 15 sites in China
- Volunteers
- 8,252 people
- Sponsor
- China Medical University, China
Diabetes Mellitus, Type 2, Adverse Event
Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes
Lowering of blood pressure (BP) in high-risk hypertensive individuals reduces major adverse cardiovascular and cerebrovascular events. Diabetic patients with hypertension benefit from BP lowering treatment.
- Conditions
- Diabetes Mellitus, Type 2, Adverse Event, Blood Pressure, Prehypertension
- Trial name
- IPAD (NCT03264352)
- Testing
- Allisartan Isoproxil, Amlodipine 5mg, Standard treatment by current guideline
- Where
- China
- Volunteers
- 11,414 people
- Sponsor
- XueQing Yu
Coarctation of Aorta, High Blood Pressure
A Study of Angiotensin-II Receptor Blocker on Cardiovascular Remodeling (VALUE Trial)
The purpose of this study is to evaluate the effectiveness and mechanism of action of Losartan in the treatment of coarctation of aorta.
- Trial name
- VALUE (NCT06150560)
- Testing
- Losartan, Amlodipine
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Mayo Clinic
Hypertension
Effectiveness and Safety of Sequential Triple Combination Therapy (Amlodipine/Losartan/Chlorthalidone) in Korean Patients With Hypertension
A multicenter, prospective, non-interventional, observational study to evaluate effectiveness and safety of sequential triple combination therapy (amlodipine/losartan/chlorthalidone) in Korean patients with hypertension
- Trial name
- AMPR-OS-2503 (NCT07784296)
- Testing
- AMOPREL TAB 1.67/16.67/4.17mg
- Where
- South Korea
- Volunteers
- 3,500 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Hypertension, Coronary Arterial Disease
Comparative Effectiveness of Dual Antihypertensive Regimens in Patients After Percutaneous Coronary Intervention
This prospective randomized open-label study aims to compare the effectiveness of two dual antihypertensive therapy regimens in patients with arterial hypertension and coronary artery disease after elective percutaneous coronary…
- Conditions
- Hypertension, Coronary Arterial Disease, Percutaneous Coronary Intervention
- Trial name
- EDAM (NCT07683585)
- Testing
- Losartan + Hydrochlorothiazide, Amlodipine + Azilsartan
- Where
- Russia
- Volunteers
- 207 people
- Sponsor
- National Medical Research Center for Therapy and Preventive Medicine
Completed, with results posted
All 154Heart Failure With Preserved Ejection Fraction, Hypertension
BLOCKade of Calcium Channels and Beta Adrenergic Receptors for the Treatment of Hypertension in HFpEF
Heart failure with preserved ejection fraction (HFpEF) is a critical public health problem. Heart failure (HF) affects over 5 million adults in the United States (US), and is a major source of morbidity, mortality, and impaired…
- Trial name
- BLOCK HFpEF (NCT04434664)
- Testing
- Amlodipine Besylate, Metoprolol Succinate
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Pennsylvania
Hypertension
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)
The purpose of this study is to evaluate the effect of zilebesiran on systolic and diastolic blood pressure and to characterize the pharmacodynamic (PD) effects and safety of zilebesiran as add-on therapy.
- Trial name
- KARDIA-2 (NCT05103332)
- Testing
- Indapamide, Amlodipine, Olmesartan
- Where
- 110 sites in United States, Canada and 6 more
- Volunteers
- 663 people
- Sponsor
- Alnylam Pharmaceuticals
Blood Pressure, High
INTERVENCION Trial
This trial is designed to: 1. Assess the response to montherapy with : a thiazide diuretic (HCTZ), a calcium-channel blocker (CCB, amlodipine) and an angiotensin-receptor blocker (telmisartan), among hypertensive subjects who…
- Trial name
- INTERVENCION (NCT02373163)
- Testing
- Hydrochlorothiazide, Amlodipine, Telmisartan
- Where
- Peru
- Volunteers
- 166 people
- Sponsor
- Prevencion
Hypertension
Hypertension, Intracranial Pulsatility and Brain Amyloid-beta Accumulation in Older Adults (HIPAC Trial)
The aim of this study is to determine if lowering blood pressure using FDA approved medication (antihypertensive drugs) alters brain pulsatility and reduces brain amyloid beta protein accumulation in older adults.
- Trial name
- HIPAC (NCT03354143)
- Testing
- Standard Care, Intensive Treatment
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Hypertension
Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension
Recent hypertension guidelines recommend combination therapy as initial treatment for many or most patients. Several trials suggest triple low-dose combination therapy may be highly effective in terms of achieving blood pressure…
- Trial name
- GMRx2_PCT (NCT04518306)
- Testing
- Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg, Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg
- Where
- 47 sites in United States, Australia and 3 more
- Volunteers
- 755 people
- Sponsor
- George Medicines PTY Limited